|
||
|
| Home |  |
Firm Description | |
Sectors Covered | |
Completed Transactions | |
Testimonials | |
Principals | |
M&A Report and Publications |
|
Contact Us | |
| Acquiring Party | Edwards Lifesciences Corporation (NYSE:EW), a developer of advanced cardiovascular disease products. |
|---|---|
| Transferring Party | Ethicon, Inc., a unit of Johnson & Johnson. |
| Sector | Medical Devices |
| Date | December 26, 2007 |
| Analysis Edwards picks up systems for minimally invasive heart valve surgery such as soft-tissue retractors, tubes for use in veins and arteries, catheters, and reusable instruments. Edwards, which is conducting clinical trials on catheter-based replacements for heart valves, predicted today that it will sell more than $2m of CardioVations products in 2008. Deal value -- $27m. | |
The Walden Group is a leading healthcare investment banking firm specializing in mergers, acquisitions and strategic transactions. It also invests its own funds and, together with its expert operational partners, provides value-added services to help special companies reach critical milestones. This information is copyright © 2004-2007 The Walden Group, Inc. This information is provided as a service to the public but remains the intellectual property of The Walden Group, Inc and may not be reproduced in any manner without the written permission of The Walden Group, Inc. The information contained in the transactions table was derived from publicly available and other sources. Transaction analysis and other information are based, in part, upon public comments, Walden Group research and judgments, and reporting and research of others. The information is not intended to be relied upon as pronouncements by the transaction participants or for any other reason. | |